The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2015Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression
Study Rationale:
A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s... -
Improved Biomarkers and Clinical Outcome Measures, 2015Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes
Study Rationale:
Breath analysis has the potential to be a powerful non-invasive screening tool to help a clinician determine the need for additional more invasive tests, a tool...
-
Research Grant, 2015Neurorestorative Effects of a Sigma-1 Receptor Agonist in a Model of Parkinson’s Disease
Study Rationale:
In a previous MJFF-sponsored project, we evaluated PRE-084 (an experimental compound binding to the sigma-1 receptor) in pre-clinical models of Parkinson’s disease... -
Research Grant, 2015Development of a Radioligand for Imaging of Alpha-synuclein with Positron Emission Tomography
Study Rationale:
The visualization of alpha-synuclein deposition in the living human brain is of high need as a biomarker for Parkinson´s disease (PD). Positron emission tomography... -
Target Validation, 2015Synapsin III: A Novel Therapeutic Target for Parkinson’s Disease
Objective/Rationale:
In Parkinson’s disease (PD) accumulation of alpha-synuclein at striatal synapses, the neuronal sites of dopamine release, is believed to trigger cell degeneration. We have found... -
Research Grant, 2015Delivery of Cerebral Dopamine Neurotrophic Factor with Microbubbles and MRI-guided Focused Ultrasound (Supplement)
Promising Outcomes of Original Grant:
We achieved our key goal of non-invasive, targeted delivery of therapeutic doses of CDNF drug to the brain regions affected by Parkinson’s [striatum (ST) and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.